23138-53-6Relevant articles and documents
Tris(2-aminoethyl)amine, a suitable spacer for phosphate and sulphate receptors
Raposo, Cesar,Almaraz, Marta,Martin, Mercedes,Weinrich, Volker,Mussons, M Luisa,et al.
, p. 759 - 760 (1995)
Tris(2-aminoethyl)amine and cis-1,3,5-tris(aminomethyl)cyclohexane have been checked as spacers for phosphate receptors.Ureas are better binding arms then thioureas for these spacers while the combination of this first functional group with chromenone fra
Chloride transport activities of trans- and cis-amide-linked bisureas
Park, Eun Bit,Jeong, Kyu-Sung
supporting information, p. 9197 - 9200 (2015/06/02)
Of the bisurea compounds linked through trans- and cis-benzanilide spacers, the cis-amide derivatives were found to be effective in chloride transport, using which a stimuli-responsive mobile carrier was devised. This journal is
Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold
Aravapalli, Sridhar,Lai, Huiguo,Teramoto, Tadahisa,Alliston, Kevin R.,Lushington, Gerald H.,Ferguson, Eron L.,Padmanabhan,Groutas, William C.
experimental part, p. 4140 - 4148 (2012/09/08)
Dengue and West Nile viruses (WNV) are mosquito-borne members of flaviviruses that cause significant morbidity and mortality. There is no approved vaccine or antiviral drugs for human use to date. In this study, a series of functionalized meta and para aminobenzamide derivatives were synthesized and subsequently screened in vitro against Dengue virus and West Nile virus proteases. Four active compounds were identified which showed comparable activity toward the two proteases and shared in common a meta or para(phenoxy)phenyl group. The inhibition constants (Ki) for the most potent compound 7n against Dengue and West Nile virus proteases were 8.77 and 5.55 μM, respectively. The kinetics data support a competitive mode of inhibition of both proteases by compound 7n. This conclusion is further supported by molecular modeling. This study reveals a new chemical scaffold which is amenable to further optimization to yield potent inhibitors of the viral proteases via the combined utilization of iterative medicinal chemistry/structure-activity relationship studies and in vitro screening.